
Keywords: CTC, circulating tumor cells; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; NACT, neoadjuvant chemotherapy; OS, overall survival; PR, progesterone; RFS, relapse-free survival; TNM, Tumor Node Metastasis